(total: +22 %; dimer: +54 %; p < 0.001). Conversely, mGluR5 regulatory proteins were expressed at lower levels in schizophrenia subjects compared to controls (Norbin −37 %, p < 0.001; Tamalin −30 %, p = 0.084; Preso1 −29 %, p = 0.001). mGluR5 protein was significantly associated with mGluR5 mRNA and mGluR5 endogenous regulators in control subjects, but these associations were lost in schizophrenia subjects. Lastly, there were no associations between protein measures and lifetime antipsychotic history in schizophrenia subjects. To confirm no antipsychotic influence, all proteins were measured in the prefrontal cortex of rats exposed to haloperidol or olanzapine; there were no effects of antipsychotic drug treatment on mGluR5, Norbin, Tamalin or Preso1. The results from our study provide compelling evidence that mGluR5 regulation is altered in schizophrenia, likely contributing to the altered glutamatergic signaling that is associated with the disorder.
Introduction
Deficits in executive function, reasoning abilities and working memory seen in individuals with schizophrenia are largely attributable to altered glutamate signaling in cortical regions [13] . These neurocognitive deficits are arguably the most debilitating aspects of the disorder, and the most difficult to treat [33] . While we and others have found changes in the main cortical ionotropic glutamate receptor, the N-methyl-d-aspartate receptor (NMDAR) in schizophrenia [1, 39] , other glutamate receptors are likely to be involved. Accumulating evidence strongly suggests the involvement of metabotropic glutamate receptor Abstract Knockout of genes encoding metabotropic glutamate receptor 5 (mGluR5) or its endogenous regulators, such as Norbin, induce a schizophrenia-like phenotype in rodents, suggesting dysregulation of mGluR5 in schizophrenia. Human genetic and pharmacological animal studies support this hypothesis, but no studies have explored mGluR5 dysfunction at the molecular level in the postmortem schizophrenia brain. We assessed mGluR5 mRNA and protein levels in the dorsolateral prefrontal cortex (DLPFC) using a large cohort of schizophrenia and control subjects (n = 37/group), and additionally measured protein levels of recently discovered mGluR5 endogenous regulators, Norbin (neurochondrin), Tamalin (GRASP-1), and Preso1 (FRMPD4), which regulate mGluR5 localization, internalization and signaling. While mGluR5 mRNA expression was unchanged, mGluR5 protein levels were significantly higher in schizophrenia subjects compared to controls Electronic supplementary material The online version of this article (doi:10.1007/s00401-015-1411-6) contains supplementary material, which is available to authorized users. subtype 5 (mGluR5) in the emergence of glutamate deficits in schizophrenia. First, mGluR5 antagonism in rodents produces a range of schizophrenia-related behaviors, such as deficits in social interaction, working and spatial memory, instrumental learning, and amplification of deficits induced by NMDAR antagonists. Second, mGluR5 knockout mice display schizophrenia-like behaviors, including reduced sensorimotor gating, impaired spatial memory, and sensitivity to deficits induced by NMDAR antagonists or amphetamine. Finally, mGluR5-positive allosteric modulators (PAMs) have therapeutic potential in the treatment of schizophrenia-like behaviors, particularly the cognitivelike symptoms which are induced in both glutamatergic (NMDAR antagonists) and dopaminergic (amphetamine) animal models (see [18] ).
Based on these studies, a role of mGluR5 in schizophrenia pathophysiology has been hypothesized. Ohnuma and colleagues [25] first reported that mGluR5 mRNA expression was increased in pyramidal cell layers of the superior frontal cortex (Brodmann Area 9; BA9) of schizophrenia subjects, although more recently, no change was reported in a larger cohort examining the same region [8] . Conversely, mGluR5 monomer protein levels were reported to be significantly reduced in BA9 in the same study [8] . However, other postmortem studies in cortical regions of subjects with schizophrenia have reported that mGluR5 mRNA, protein and binding levels are unaltered (see [18, 23] ). These inconsistent results might be due to region-specific differences, small sample sizes and/ or other methodological differences in protein detection, such as the examination of monomer versus dimer protein expression [23] . A potential explanation for pathological disturbances in mGluR5 is abnormal regulation, caused by alterations to key proteins that regulate mGluR5 signaling, localization and trafficking as previously suggested by us [23] and others [4] . These types of disturbances have been previously reported for other aspects of the glutamatergic system [19] . In support of this hypothesis, proteins that regulate glutamatergic receptors (e.g., NMDAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and mGluRs), including Homer1, are reportedly altered in some schizophrenia studies (see [35] ). However, additional proteins that critically modulate mGluR5 activity have also been identified [12, 14, 37] , but have not yet been directly examined in the brains of people with schizophrenia.
Of the known mGluR5 endogenous regulators, Norbin, Tamalin and Preso1 have particularly distinctive roles in mGluR5 modulation. The cytoplasmic protein Norbin (neurochondrin) is reported to increase mGluR5 cell surface localization and positively regulate mGluR5 signaling in in vitro systems [38] . Norbin is also critically involved in neurite outgrowth, and thus neuronal plasticity and cognitive functioning [22, 30] . Cortical Norbin knockout mice have reduced mGluR5 cell surface expression and function, and display strong schizophrenia-like behaviors [38] . Tamalin (also named GRP1-associated scaffold protein1 or GRASP-1) is a 95 kDa postsynaptic density protein (PSD-95)/discs-large/ZO-1 or PDZ) domain-containing scaffold, which plays a fundamental role in the localization of mGluR5 from the soma to the neuritic processes in cultured hippocampal neurons [14] . In accordance, disruption of Tamalin/mGluR5 couplings causes reduced mGluR5 cell surface expression and increased agonist-induced internalization of mGluR5 in cellular assays [34] . Furthermore, the scaffold protein Preso1 (FRMPD4) was also reported to be essential to mGluR5 signaling, with Preso1-dependent phosphorylation of mGluR5 acting to downregulate mGluR5 signaling under control conditions in cellular assays, while Preso1 −/− mice exhibit characteristics reminiscent of enhanced mGluR5 signaling [12] . Preso1 additionally modulates mGluR5 coupling to the scaffold protein Homer [12] , which has been previously associated with schizophrenia [6, 31] . However, the role of Preso1 in schizophrenia-relevant paradigms has not been assessed. Together, Norbin, Tamalin and Preso1 have been shown to critically modulate mGluR5 localization, trafficking and signaling, and may thus serve as markers of these functions in postmortem studies where manipulation of the signaling system is not possible. Furthermore, considering that mGluR5 activity could be impaired if these endogenous regulators are altered, it is crucial that they are considered in the context of schizophrenia.
We therefore explored in the present study whether subjects with schizophrenia express altered mRNA and protein levels of mGluR5 compared to controls, in a well-powered postmortem cohort. We specifically examined the dorsolateral prefrontal cortex (DLPFC; BA46) as this region is highly implicated in schizophrenia pathology due to its role in the development of cognitive deficits [2, 39] . For the first time, we also assessed the protein levels of novel mGluR5 endogenous regulators, Norbin, Tamalin and Preso1, as markers of mGluR5 localization, trafficking and signaling. Based on the extensive evidence that reduction of mGluR5 activity causes behavioral phenotypes associated with schizophrenia (see [18] ), our hypotheses were that levels of mGluR5 and mGluR5 endogenous modulators would be decreased in the DLPFC of people with schizophrenia. Considering that premortem medication history is a confounding factor in human postmortem studies, we also investigated whether the influences of commonly used antipsychotic drug treatments extend to the mGluR5 system. We therefore conducted the same protein analyses in a pharmacological animal model exposed to typical (haloperidol) or atypical (olanzapine) antipsychotic medication.
Materials and methods

Human postmortem brain samples
Human DLPFC tissues were obtained from the New South Wales Brain Bank Network (Sydney, Australia). The complete cohort consisted of 37 schizophrenia (including 7 schizoaffective) postmortem brain samples and 37 controls (with no history of psychiatric diagnosis), which were matched according to tissue pH, age at death, postmortem interval and RNA integrity number (RIN) ( Table 1) . Schizophrenia subjects were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders IV. Antipsychotic drug treatment premortem was standardized to lifetime chlorpromazine equivalent for each patient. Antidepressant drug treatment history was also specified on a qualitative scale (i.e., yes/no). Further details regarding clinical, demographic and tissue characterization of the cohort have been described previously [40] . This study was approved by the Human Research Ethics Committees at the University of Wollongong (HE99/222) and the University of New South Wales (HREC07261).
Human brain tissue preparation
Anatomical identification and preparation of the tissue have been previously described in detail [40] . Briefly, samples corresponding to BA46 were dissected from coronal blocks from the middle frontal gyrus, anterior to the genu of the corpus callosum. For gene expression analyses, 300 mg of frozen tissue was pulverized on dry ice. Trizol was used to extract total RNA, and the quality was analyzed using the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, USA). For immunoblot studies, 40 mg of frozen tissue was homogenized in 400 µL of homogenizing buffer, containing 50 mM Tris pH 7.5, 50 % glycerol and 1:20 (by volume) protease inhibitor cocktail (Sigma, Sydney, Australia). Homogenates were diluted to a total protein concentration of 2 µg/µl, and concentration was verified by Bradford and bicinchoninic acid assays.
Animal housing and treatment
This study was designed to assess whether commonly used antipsychotic medications affect the protein expression of mGluR5 and mGluR5 endogenous regulators. Adult male Sprague-Dawley rats at 10 weeks of age were purchased from the Animal Resource Centre (Perth, Australia) and single housed under standard conditions with food and water available ad libitum. It should be noted that although animals were singly housed to ensure accurate dosage of antipsychotic drugs, measures were taken to ensure animals were not socially isolated: wire cages were stored in an adjoining manner to allow for social interaction between cages, and animals were given pipes for hiding and wooden toys to chew, to reduce any stress caused by separation.
After 1 week of acclimatization, rats were distributed into 9 treatment groups (3 treatments × 3 treatment durations; n = 6/group), as described previously [17] . Animals were fed prepared food pellets 3 times/day at 8 h intervals, containing either: (1) typical antipsychotic, haloperidol (0.1 mg/kg body weight; daily total 0.3 mg/kg), (2) atypical antipsychotic, olanzapine (1 mg/kg body weight; daily total 3 mg/kg), (3) vehicle control (empty food pellets), for short-term (8 days), medium-term (15 days) and long-term (35 days) durations. Consumption of food pellets was visually validated. Antipsychotic doses and treatment durations were chosen to model a clinical setting [11, 41] . All animal experiments in this study were approved by the University of Wollongong Animal Ethics Committee (AE10/18) and complied with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
Animal brain tissue preparation
Rats were euthanized 48 h following the final treatment using carbon dioxide asphyxiation. Brains were rapidly removed, and the prefrontal cortex (PFC; prelimbic area, Bregma 3.7-2.7) was dissected on ice, snap frozen in liquid nitrogen, and stored at −80 °C. Identification of rat brain regions for quantification was based on a standard rat brain atlas [26] . Tissue was homogenized in NP-40 lysis buffer (Invitrogen), containing beta-glycerophosphate and phenylmethanesulfonyl fluoride protease cocktail inhibitor cocktail (Sigma). Protein concentration was determined by detergent-compatible colorimetric assay (BioRad, Gladesville, Australia), according to the manufacturer's instructions.
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis
Transcript levels of mGluR5 mRNA were measured by qRT-PCR as previously described [40] . Briefly, total RNA was extracted using Trizol as per the manufacturer's protocol (Invitrogen) and RNA quality was determined using Agilent Bioanalyzer. Complementary DNA synthesis was performed using Superscript III (Invitrogen), in triplicate and using 3 µg total RNA per sample (pooled). qRT-PCR for mGluR5 mRNA was subsequently performed using TaqMan Gene Expression Assays (Applied Biosystems, Hs00168275_m1) and the ABI Prism 7900HT system. Quantity mean for expression was normalized to four housekeeping genes-ubiquitin C (Hs00824723-m1), β-actin (Hs99999903-m1), glyceraldehyde-3-phosphate dehydrogenase (Hs99999905-m1), and TATA box binding protein (Hs00427620-m1)-that have been reported not to differ between the diagnostic groups in the same brain region, same cohort and same cDNA synthesis [40] .
Immunoblot
Relative protein densities were determined by immunoblot.
The following polyclonal antibodies were used: mGluR5 (ABCAM ab27190 [17] ), Tamalin (ABCAM ab30576 [32] ), Preso1 (Santa Cruz sc-242862 [16, 27] ) and Norbin (ABCAM ab130507). Immunoblotting was performed as described previously [17] , with minor modifications optimized for the measurement of each protein of interest (Table S1 ). Samples were loaded at 5 and 10 µg for all proteins assessed in human and rat brain samples, respectively.
Samples were visualized using an enhanced chemiluminescent detection kit (BioRad). Band density was detected by the Gel Doc 2200 Pro (Carestream Molecular Imaging, USA) and quantified with Carestream MI software (v 5.0.4.44, Carestream Molecular Imaging). All bands were within the linear range of detection. Protein measures were subsequently normalized to the respective β-actin density [i.e., (band intensity of protein) ÷ (band intensity of respective β-actin)], which was unaltered in the present study and has also been reported as a reliable standard in this postmortem cohort [40] . Actin-normalized values were then renormalized to a pooled sample, which was run on each gel to control for any gel-to-gel variability. Each sample was run in duplicate and the average value of both samples was then used in the statistical analyses. Experiments and quantification were performed blind to diagnosis (human) or treatment group (rat).
Statistical analysis of human data
Statistical analyses were performed with SPSS version 19.
Significance was set to p < 0.05 and data are presented as mean ± standard error of the mean. mGluR5 mRNA expression was normally distributed. As distributions for all protein measures were skewed to the right (Kolmogorov-Smirnov: d = 0.161-0.224, p < 0.001), normalized distribution for these proteins was achieved by transforming to the natural logarithm of the relative protein values. Outliers were screened as mean ±2 standard deviations and were removed. No subjects were removed from the mRNA analysis, although 2 subjects were removed on average from each protein analysis. Analyses of variance (ANOVA) were used to detect differences in protein expression between diagnostic groups (schizophrenia/control) as well as gender (male/female), hemisphere (left/right) and antidepressant history (yes/no). Spearman's correlations were used to determine whether sample characteristics (age at death, pH, postmortem interval, RIN, brain weight and freezer storage time) were associated with protein measures. Analyses of covariance (ANCOVA) for diagnostic effects on protein expression were subsequently performed, accounting for factors that were associated with protein measures, as determined by the Spearman's correlations. Additional measures of disease characteristics were correlated specifically with the schizophrenia group (lifetime antipsychotic drug history, age of disease onset and duration of illness).
Statistical analysis of animal data
For analysis of animal data, statistics was performed with SPSS, significance was set to p < 0.05 and data are presented as the mean ± standard error of the mean. Differences between treatment (haloperidol/olanzapine/ vehicle) × duration (short term/medium term/long term) were analyzed by two-way ANOVA.
Results
Detection of mRNA and proteins
For qRT-PCR of mGluR5 mRNA, control samples (no template and no reverse transcriptase enzyme) did not produce a signal during measurement of mGluR5 mRNA expression, where we obtained robust signal from all samples and a reliable standard curve (slope = −3.42, y = 31.27). For protein measurements, mGluR5 monomer was detected as a single band at 135 kDa while the mGluR5 dimer was detected at 270 kDa. As mGluR5 was detected at two molecular weights, mGluR5 dimer and total (sum of monomer and dimer) levels are reported. We have previously reported only mGluR5 monomer levels [17] ; total and dimer measures in this study were analyzed from the same experimental run. Norbin (79 kDa) and Tamalin (96 kDa) proteins were identified as single bands at the expected molecular weights in the human DLPFC (Figs. 1a, S1 ) as well as in the rat PFC. Preso1 probing resulted in several bands; a single specific band was verified and quantified at 144 kDa by peptide preabsorption/neutralization, and all other non-specific bands thus were excluded ( Fig. S1 ; see Supplementary Methods). β-Actin was reliably detected at 45 kDa (Fig. 1a) . mGluR5 mRNA is unaltered and mGluR5 protein is increased in the DLPFC in schizophrenia mGluR5 mRNA expression was not altered in DLPFC of schizophrenia subjects compared to controls after Fig. 1 Protein levels of mGluR5 and mGluR5 signaling partners Norbin, Tamalin and Preso1 in the DLPFC of subjects with schizophrenia and matched controls. Representative β-actin is shown from mGluR5 membrane only. a Graphical depiction of percentage differences between protein measures in subjects with schizophrenia compared to control subjects, as seen in representative immunoblots. b. Normalized mGluR5 mRNA, and protein levels of mGluR5 (total and dimer). mGluR5 mRNA expression was unaltered, while mGluR5 protein expression (total and dimer) was significantly increased in schizophrenia subjects compared to controls. c Normalized protein expression of mGluR5 endogenous regulators, Norbin, Tamalin and Preso1. All mGluR5 endogenous regulators were significantly decreased in schizophrenia subjects compared to controls. Ct control, Dim dimer, DLPFC dorsolateral prefrontal cortex, Ln natural logarithm, kDa kilodaltons, mGluR5 metabotropic glutamate receptor 5, Sz schizophrenia, Tot total. *p < 0.05, **p < 0.01, ***p < 0.001 covarying for brain pH, age at death, RIN and brain weight (F 1,68 = 0.009, p = 0.924; Fig. 1b ), which were variables that correlated with mRNA expression (Table S2) . There was no effect of gender or hemisphere on mGluR5 mRNA expression. We have previously reported no change in mGluR5 monomer levels in this cohort in DLPFC [17] . However, mGluR5 dimer expression was 53.5 % higher in schizophrenia subjects compared to controls [F 1,70 = 8.688, p < 0.001; covarying for freezer storage time, which correlated with dimer levels (Table S2) : F 1,69 = 44.808, p < 0.001]. Total (monomer and dimer) mGluR5 protein was significantly increased by 21.9 % in schizophrenia subjects compared to controls (F 1,68 = 19.090, p < 0.001; Fig. 1b) . Significance was maintained after covarying for freezer storage time [F 1,67 = 17.45, p < 0.001 (correlation values in Table S2) ]. There were no effects of gender and hemisphere on mGluR5.
Norbin, Tamalin and Preso1 proteins are reduced in the DLPFC in schizophrenia
Protein levels of all three mGluR5 endogenous regulators examined were significantly decreased in schizophrenia subjects (Fig. 1c) . Specifically, Norbin was decreased by 37.4 % (F 1,70 = 34.497, p < 0.001), Tamalin by 30.4 % (F 1,70 = 4.428, p = 0.039), and Preso1 by 21.5 % (F 1,70 = 5.607, p = 0.021). Significance was maintained for Norbin and Preso1 after covarying for freezer storage time, which was significantly correlated with these protein levels (Table S2) ; however, Tamalin was not significantly different after covarying for freezer storage time and age at death (F 1,69 = 3.075, p = 0.084), due to a strong effect of freezer storage time (r = −4.75, p < 0.001) and age at death in control subjects (r = 0.353, p = 0.032; correlation values in Table S2 ). There were no effects of gender or hemisphere on Norbin, Tamalin or Preso1 protein levels (p > 0.050).
Correlations with demographic measures, disease characteristics and medication estimates
Spearman's correlations were performed to assess any relationships between mGluR5 mRNA expression and protein measures of mGluR5, Norbin, Tamalin and Preso1 with age at death, RIN, freezer storage time, brain pH, postmortem interval and brain weight (Table S2) . mGluR5 mRNA expression was significantly associated with brain pH, age at death, RIN and brain weight overall in all subjects. Specifically in control subjects, mGluR5 mRNA was negatively correlated with age at death and positively correlated with brain weight. In schizophrenia subjects, mGluR5 mRNA expression was weakly associated with pH, RIN, and brain weight. There were no effects of illness duration, age of disease onset or lifetime antipsychotic drug history on mGluR5 mRNA in schizophrenia subjects, nor were there any effects of antidepressant medication (yes/no: t-35 = 0.299, p = 0.588).
There was a significant interaction between mGluR5 total protein with freezer storage time in both control and schizophrenia subjects when analyzed separately, but not overall. mGluR5 dimer was also significantly correlated with freezer storage time an RIN in schizophrenia subjects. An effect of freezer storage time was seen on Norbin, Tamalin and Preso1. There were no other significant correlations with protein measures of mGluR5 endogenous modulators in all subjects. Specifically in control subjects, Tamalin, but not Norbin or Preso1, was negatively associated with age at death, while all proteins were associated with freezer storage time. In the schizophrenia group, there was a negative association of age of disease onset with measures of Norbin and Preso1 only, and an effect of freezer storage time on Norbin. There was no effect of illness duration or lifetime antipsychotic drug history on mGluR5 (total or dimer), Norbin, Tamalin or Preso1.
Relationships of mGluR5 protein with mGluR5 mRNA, Norbin, Tamalin and Preso1 proteins in the DLPFC
A distinct relationship was seen between mGluR5 total protein and mGluR5 mRNA expression, as well as protein measures of mGluR5 with Norbin, Tamalin and Preso1 (Fig. 2) . While mGluR5 total protein was positively associated with mGluR5 mRNA expression in control subjects (r = 0.361, p = 0.030), this correlation was lost in schizophrenia subjects. Similarly, mGluR5 protein was strongly and negatively associated with all endogenous regulators in the control group (Norbin: r = −0.657, p < 0.001; Tamalin: r = −0.560, p < 0.001; Preso1: r = −0.428, p = 0.009), but this association was not present in the schizophrenia group (Norbin: r = 0.096, p = 0.578; Tamalin: r = 0.202, p = 0.238; Preso1 r = 0.080, p = 0.644). An extensive list of correlation values is included in Table S3 .
Effects of antipsychotic drug treatment on mGluR5 and its endogenous regulators in the prefrontal cortex
To assess the effects of antipsychotic medications on the mGluR5 system, two-way ANOVA was used to compare the effects of haloperidol, olanzapine and vehicle/control treatment (8, 16 or 36 days) on protein levels of mGluR5 (total, monomer, dimer), Norbin, Tamalin and Preso1 in the PFC of rats. There were no significant main effects of treatment or duration on protein expression, nor were there any interactions between treatment and duration on protein expression (F > 0.050, p > 0.961; Fig. 3 ). This is in line with the aforementioned human studies, in which there were no effects of lifetime antipsychotic drug medication or antidepressant history on protein measures.
Discussion
Here, we provide compelling evidence that mGluR5 is dysregulated in the DLPFC (BA46) of subjects with schizophrenia. We found that while mGluR5 mRNA expression levels were not different, mGluR5 protein levels were significantly higher in schizophrenia subjects compared to controls (total: +22 %; dimer: +54 %). Conversely, in the same samples, mGluR5 endogenous regulators Norbin (−37 %), Tamalin (−30 %; p = 0.084 after covarying for confounding factors) and Preso1 (−29 %) were expressed at substantially lower levels in the DLPFC of schizophrenia subjects compared to control subjects. mGluR5 mRNA, Norbin, Tamalin and Preso1 proteins were significantly Fig. 2 Correlation plots depicting the relationship between mGluR5 protein and mGluR5 mRNA, and protein levels of mGluR5 endogenous regulators. mGluR5 protein was positively associated with mGluR5 mRNA in the control group, but not the schizophrenia group. Furthermore, protein measures of mGluR5 and its endogenous regulators were strongly and negatively associated in the control group, however, this association was lost in the schizophrenia group Fig. 3 Effects of current antipsychotic drug treatment on mGluR5, Norbin, Tamalin and Preso1. Protein levels in the prefrontal cortex of rats treated for 8, 16 or 36 days with haloperidol (0.3 mg/kg/day) or olanzapine (3 mg/kg/day). There were no significant effects of antipsychotic drug treatment on levels of mGluR5 or its endogenous regulators associated with mGluR5 protein levels in control subjects, but these associations were lost in schizophrenia subjects. Lastly, there was no effect of current antipsychotic drug treatment on mGluR5 or mGluR5 endogenous regulators in either human or animal studies. Thus, the present findings suggest that mGluR5 regulation is altered in the DLPFC in schizophrenia, but not influenced by current therapeutics.
In this study, higher mGluR5 protein expression was detected in schizophrenia subjects compared to controls, but there was no difference in mGluR5 mRNA expression in these same cases. Previous studies have similarly reported no change in mGluR5 mRNA expression in the adjacent BA9 region of schizophrenia subjects [8, 36] accompanied by altered mGluR5 protein levels [8] . These findings support the existence of dissociation between mGluR5 mRNA and protein levels in schizophrenia subjects. Our results also revealed that mGluR5 mRNA expression was significantly and positively associated with mGluR5 protein in control subjects, but not schizophrenia subjects. mRNA and protein have differing half-lives due to variations in protein synthesis and degradation, so that the change in protein concentration is equal to the "rate of translation" minus the "rate of degradation" [10] . As we report no change in the rate of translation (as measured by mGluR5 mRNA expression), the loss of association between mGluR5 mRNA and protein in schizophrenia is likely indicative of reduced receptor degradation and a prolonged lifespan of mGluR5 proteins. This may be owing to slowed mGluR5 trafficking, as we further report reduced levels of the mGluR5 trafficking proteins Norbin and Tamalin in this study; however, we caution that Tamalin did not reach significance after covarying for confounding factors (p = 0.084), but due to the large magnitude of change (30 %) and significant correlations of Tamalin with the other measures ( Fig. 4c ; Table S3 , and discussed below), we will further discuss this finding.
Norbin and Tamalin bind to amino acid residues on the intracellular terminus of mGluR5, and critically regulate mGluR5 cell surface localization and intracellular trafficking [14, 15, 34, 38] . Accordingly, in cultures derived from cortical Norbin knockout mice, mGluR5 cell surface localization was reduced [38] . Kitano and colleagues [14] also determined that Tamalin was required for transport of mGluR5 from the soma to neuritic processes, while Timms et al. [34] demonstrated that deletion of the Tamalin-binding site on mGluR5 resulted in increased agonist-dependent internalization of mGluR5. This evidence suggests reductions in Norbin and Tamalin simultaneously cause reduced trafficking of mGluR5 protein, decreased cell surface expression, and intracellular retention of mGluR5 (Fig. 4a,  b) . In view of the fact that G-protein-coupled receptor dimerization occurs soon after biosynthesis [20] , it is also likely that these captive mGluR5 are in the dimer form. A growing body of evidence suggests that mGluR5 proteins are only functional in the form of disulfide-linked dimers [5, 29] , suggesting an increase in mGluR5 dimers represents an increase in functional mGluR5 units in the present study. However, considering reduced mGluR5 signaling (by mGluR5 knockout or pharmacological antagonism) produces schizophrenia-like behaviors, and mGluR5 PAMs have therapeutic efficacy in preclinical rodent models (see [18] ), we hypothesize a model of mGluR5 dysregulation in which higher protein expression and dimer units does not represent increased activity and/or function in the schizophrenia brain, but rather, alterations to mGluR5 localization (Fig. 4a, b ) and also signaling (Fig. 4a, c) .
In addition to a trafficking deficit, our results further indicate altered mGluR5 signaling as substantial reductions were observed in Norbin and Preso1 proteins, which are critical regulators of mGluR5 signaling [12, 38] . First, Norbin was demonstrated to enhance mGluR5 signaling in cell-based assays, by increasing inositol phosphates, intracellular calcium release, and ERK1/2 phosphorylation compared to mGluR5 expression alone [38] , indicating decreased mGluR5 signaling due to reduced Norbin expression in the present study (Fig. 4a) . In contrast, Preso1 reportedly inhibits mGluR5-dependent intracellular release and ERK1/2 phosphorylation, via Homer1/2/3 under control conditions [12] , indicating disinhibition of mGluR5 signaling due to reduced Preso1 in the present study (Fig. 4c) . Notably, Preso1 and Norbin levels are positively correlated in control subjects (r = 0.559, p = 0.003) but not schizophrenia subjects (r = 0.152, p = 0.368), supporting the notion of opposing functions and thus a balance of Norbin:Preso1 under control conditions. Although further studies will be required to determine whether reductions in Norbin and Preso1 are causal or compensatory to mGluR5 dysregulation, this finding suggests that the ratio of Norbin:Preso1 and thus positive and negative modulation of mGluR5 is altered in schizophrenia, strongly supporting the hypothesis that mGluR5 signaling is affected in the DLPFC in the schizophrenia brain.
It should be noted that the increase in mGluR5 protein levels in the present study was specific to mGluR5 dimers, as we previously reported no change in mGluR5 monomers in the same samples in the same experimental run [17] . As discussed previously by Corti et al. [3] , who similarly reported altered dimerization of mGluR3 in the DLPFC in schizophrenia and hypothesized the same of mGluR5 [4] , there are several possible interpretations of altered monomer and dimer densities. First, the composition of heterodimeric complexes involving mGluR5 with structurally similar G-protein coupled receptors [such as mGluR1a, adenosine or gamma-aminobutyric acid (GABA)-B receptors] has been proposed [9, 29] , presenting the possibility of alterations to the ratio of heterodimers: homodimers, and thus mGluR5 function and activity in schizophrenia. Furthermore, as hypothesized for mGluR3, the presence of mutations within mGluR5 and/or altered splicing of mGluR5 might affect the formation, affinity and activity of mGluR5 dimers [3, 34] . Lastly, it remains unclear whether dimerization might be affected during the perimortem period, or whether dimers measured under reducing immunoblot conditions are reflective of physiological levels [7, 23] . Even so, considering we found an increase rather than a decrease in mGluR5 dimer levels, it is unlikely that these factors impact on the overall results of this study. Further, the mechanisms or molecules responsible for regulating mGluR5 dimerization are not known but would be useful for interpreting these findings. It is additionally interesting that in the present study, the levels of all measured mGluR5 endogenous regulators were negatively correlated with protein levels of mGluR5 in control subjects, and this association was lost in subjects with schizophrenia (Table S3) . Although this finding supports the dissociation of mGluR5 with endogenous regulatory processes in the schizophrenia brain, the negative association between mGluR5 and its endogenous regulators under control conditions is counterintuitive and requires further investigation.
We found no associations between mGluR5 and its endogenous regulators with lifetime antipsychotic drug treatment in our postmortem human study, and no effects of haloperidol or olanzapine treatment on the expression of the mGluR5 system proteins in our animal study. Our results thus strongly suggest that the aspects of the mGluR5 system measured in this report are unaffected by commonly Fig. 4 Proposed model of mGluR5 dysregulation. In all panels (a-c), control conditions are depicted on the left, while a proposed model of mGluR5 dysregulation is depicted on the right. a Under controlled conditions, Norbin (pink) promotes mGluR5 cell surface expression and positively regulates mGluR5 signaling [38] . In schizophrenia, reduced levels of Norbin are proposed to result in decreased mGluR5 surface expression, resulting in intracellular retention of mGluR5 and reduced mGluR5 signaling. b Tamalin reportedly modulates mGluR5 cell-surface expression [34] as well as trafficking mGluR5 from the soma to the neuritic processes [14] . In schizophrenia, reduced levels of Tamalin protein are hypothesized to cause decreased mGluR5 cell surface expression due to agonist-induced internalization and impaired intracellular trafficking of mGluR5, leading to intracellular retention. c Under control conditions, Preso1 is an inhibitor of mGluR5 signaling by reducing release of calcium from intracellular stores, inhibiting downstream signaling [12, 28] ; thus reduced levels of Preso1 in schizophrenia is proposed to disinhibit mGluR5 signaling and result in increased intracellular calcium concentrations and downstream signaling 1 3 used antipsychotic drugs. This is in line with our previous work, in which we found that mGluR5 binding in the PFC was also unaffected in the same animal model and treatment regime [17] . It is notable, however, that these results are reflective of "control" conditions, which would be enhanced by follow-up studies of antipsychotic drug treatment in an animal model of schizophrenia. Drugs targeting mGluR5 have therapeutic efficacy against cognitive and negative schizophrenia-like deficits in animal models [24] , while current therapeutics have little efficacy for these symptoms [21] . mGluR5-targeting drugs, therefore, present a promising adjunct treatment strategy for schizophrenia, specifically in relation to cognitive deficits associated with glutamatergic dysfunction. However, it should be specifically determined whether mGluR5 target availability is altered in people with schizophrenia due to intracellular retention, and whether this will impair the efficacy of novel therapeutics aimed at mGluR5.
Using one of the largest postmortem cohorts to date to study mGluR5 and its endogenous regulators, we have for the first time established that mGluR5 is dysregulated in schizophrenia. Due to the prominent role of cortical glutamate function in the emergence of emotional and cognitive deficits associated with schizophrenia, we further suggest that dysregulation of mGluR5 might contribute to the cognitive dysfunctions that are observed in these individuals. While this study supports the presence of mGluR5 dysregulation and/or signaling deficits in schizophrenia, it is important to determine whether mGluR5 target availability is altered, and whether this will impair the efficacy of novel therapeutics aimed directly at mGluR5. Future postmortem studies focusing on functional assays and analyses of protein-protein interactions in specific neuronal populations and/or subcellular compartments are thus required to examine the nature of functional alterations to mGluR5 (for example, altered phosphorylation, protein misfolding, reduced protein interactions, and/or sequence mutations). Further studies investigating the basic processes involved in mGluR5 translation, dimerization and regulation (under control conditions) will also be helpful in determining the exact processes underlying mGluR5 regulation, the role of mGluR5 in schizophrenia pathology, and how this may impact on novel therapeutics aimed at mGluR5.
